Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Executive Summary

Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.

Advertisement

Related Content

FDA Warns Apotex Management To Demand Quality, Meet Specs
The Baxter/Claris Warning Letter: Out Of Spec, Out Of Mind
Manufacturing Compliance Updates In Brief From US FDA And EU
Fresenius Kabi Hit With Two Warning Letters At Sites In India In December
FDA’s Revised Quality Metrics Program: Voluntary Now, Mandatory Later

Topics

Advertisement
UsernamePublicRestriction

Register

PS124459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel